Brain Health Champions: Prevention of Cognitive Decline Through Patient Engagement and Risk Management

CE Information

1.75 contact hours

Completion Time

1 hour, 45 minutes

Available Until

January 26, 2026

Posted By

PCE

Ready to start this activity?

Navigate

Overview

Specialties

Adult, Family, Gerontological, Psychiatric / Mental Health, and Women's Health

Subspecialties

Neurology

Clinical Topics

Dementia and Geriatric Medicine

Watch an on-demand webcast of an expert faculty presentation and strategies to improve patients’ brain health through engagement and risk management as a measure to prevent cognitive decline.

Learning Objectives

Upon completion of this activity, participants should be able to:

Assess the benefits of optimizing brain health to prevent cognitive decline before it occurs
Analyze the evidence for the use of testing to detect AD pathology before symptoms emerge
Implement effective practices for discussing brain health and cognitive decline prevention with patients during routine care
Evaluate for known modifiable risk factors for cognitive decline and dementia at patient visits

CE Information

This activity offers 1.75 contact hours to attendees.

Accredited by AAPA, ANCC, IPCE.

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Nursing Continuing Professional Development

The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 1.75 contact hours.

Physician Associate Continuing Medical Education

Clinical Care Options, LLC has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.75 AAPA Category 1 CME credits. Approval is valid until January 26, 2026. PAs should only claim credit commensurate with the extent of their participation.

Disclosures

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Alireza Atri, MD, PhD

Chief Medical Officer, Banner Research
Phoenix, Tucson and Sun City, Arizona
Director, Banner Sun Health Research Institute
Sun City, Arizona

Alireza Atri, MD, PhD: researcher (paid to institution): Alzheon, Athira, Biohaven, Biogen, Eisai, Lilly, Vivoryon; consultant/advisor: AriBio, Axsome, Eisai, Lantheus, Life Molecular Imaging, Lundbeck, Merck, Novo Nordisk, ONO, Prothena, Vaxxinity.

Sharon A. Brangman, MD

Distinguished Service Professor
Chair, Department of Geriatrics
Director, Upstate Center of Excellence for Alzheimer's Disease
SUNY Upstate Medical University
Syracuse, New York

Sharon A. Brangman, MD: consultant/advisor/speaker: Eisai.

Sharon Cohen, MD, FRCPC

Medical Director
Toronto Memory Program
Toronto, Ontario, Canada

Sharon Cohen, MD, FRCPC: researcher: AbbVie, AgeneBio, Alector, Alnylam, Alzheon, Anavex, Biogen, Bristol Myers Squibb, Cassava Sciences, Eisai, Eli Lilly, GAP, GlaxoSmithKline, INmune Bio, Janssen, Novo Nordisk, RetiSpec, Roche, UCB Biopharma; consultant/advisor/speaker: Alnylam, Biogen, Biohaven, Bristol Myers Squibb, Cassava Sciences, Cognivue, Cogstate, Eisai, Eli Lilly, GlaxoSmithKline, INmune Bio, Kisbee Therapeutics, Lundbeck, Novartis, Novo Nordisk, Parexel, RetiSpec, Roche, SciNeuro Pharmaceuticals.

Anton P. Porsteinsson, MD

William B. and Sheila Konar Professor of Psychiatry, Neurology, and Neuroscience, and Medicine
Director, Alzheimer's Disease Care, Research and Education Program (AD-CARE)
University of Rochester School of Medicine and Dentistry
Rochester, New York

Anton P. Porsteinsson, MD: consultant/advisor/speaker: Acadia, Athira, Axsome, Biogen, Bristol Myers Squibb, Cognition Therapeutics, Lundeck, Novo Nordisk, ONO, Otsuka, Xenon; researcher: Alector, Athira, Cassava, Eisai, Lilly, Roche, Vaccinex.

Elizabeth Poynor, MD, PhD

Chair of Women's Health and Gynecology
Atria Health Institute
New York, New York

Elizabeth Poynor, MD, PhD, has no relevant financial relationships to disclose.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose, except Michael Asbach, DMSc, PA-C, as noted below.

Michael Asbach, DMSc, PA-C: consultant/advisor/speaker: AbbVie, Axsome, Bristol Myers Squibb, Intra-Cellular Therapies, Janssen, Neurocrine, Otsuka, Sage/Biogen, Teva.

Ready to start this activity?

Login required. You will be redirected to an external website to register for and complete this activity.

Back to navigate